Solvonis Therapeutics (LSE: SVNS), a late clinical-stage biopharmaceutical company developing small-molecule treatments for central nervous system disorders, said the European Patent Office has issued a Notice of Allowance for a composition-of-matter patent covering its post-traumatic stress disorder (PTSD) programme.
The patent relates to SVN-114, the company's lead PTSD candidate, and represents the strongest form of pharmaceutical intellectual property protection, covering the chemical compounds themselves rather than just formulation or use.
Solvonis has developed three additional chemically distinct supporting patent families through the programme, all of which have now achieved composition-of-matter grant or allowance in either the US or Europe.
A corresponding US application remains pending, with examination also requested in Canada.
PTSD affects an estimated 15.8 million people across the US, UK, EU4 and Japan, with approved pharmacological treatments available.
Solvonis pointed to Otsuka Pharmaceutical's acquisition of Transcend Therapeutics in June, worth up to $1.225 billion including contingent payments, as a benchmark for pharmaceutical investment in the PTSD field.
SVN-114 is designed to reduce cardiovascular burden and abuse potential compared with existing treatments in development, using a soft-drug design intended to shorten the treatment window.
"This allowance strengthens the proprietary position around SVN-114 in a large PTSD market attracting significant pharmaceutical investment," said chief executive Anthony Tennyson.
Solvonis plans further pharmacology, pharmacokinetic and safety studies, and intends to pursue non-dilutive grant funding in the UK, EU and US to advance SVN-114 towards IND-enabling development.
News Intelligence what this means for the company
Solvonis has secured European Patent Office allowance for a composition-of-matter patent on SVN-114, its lead PTSD candidate—the strongest form of IP protection, covering the chemical compounds themselves. The company has now built a four-patent-family portfolio around the programme, with three additional families already granted or allowed in the US or Europe. This is a routine but material IP milestone for a pre-revenue clinical-stage company; it does not advance the drug toward clinic or reduce development risk, but it does lock down exclusivity in a market Solvonis benchmarked against Otsuka's $1.225 billion acquisition of Transcend Therapeutics.
Patent allowance strengthens Solvonis's competitive moat around SVN-114 in PTSD, but the company remains pre-revenue and capital-dependent. The milestone does not alter the core risk profile—clinical efficacy, safety, and regulatory approval remain the binding constraints on value creation.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
